肿瘤细胞治疗研究
英文原题：Molecular understanding and clinical outcomes of CAR T cell therapy in the treatment of urological tumors.
Molecular understanding and clinical outcomes of CAR T cell therapy in the treatment of urological tumors.
泌尿系统肿瘤相对常见，约占美国所有新发癌症的 24%。
近年来，嵌合抗原受体工程化 T（CAR T）细胞疗法迅速发展，深刻推动了肿瘤学进步，尤其是血液系统恶性肿瘤领域。然而，受免疫抑制性肿瘤微环境、抗原逃逸及其他多种因素影响，其在实体瘤中的应用发展较慢。泌尿系统肿瘤较为常见，约占美国所有新发癌症的 24%。CAR T 细胞治疗泌尿系统肿瘤具有巨大潜力。本综述总结 CAR T 细胞疗法在泌尿系统肿瘤中的最新进展，包括肾癌、膀胱癌和前列腺癌，并概述迄今开发的不同代 CAR T 细胞、其信号通路和靶点。最后，本文深入讨论 CAR T 细胞疗法当前的优势、问题和副作用，并结合现有不足提出潜在的未来发展方向。
Chimeric antigen receptor engineered T (CAR T) cell therapy has developed rapidly in recent years, leading to profound developments in oncology, especially for hematologic malignancies. However, given the pressure of immunosuppressive tumor microenvironments, antigen escape, and diverse other factors, its application in solid tumors is less developed. Urinary system tumors are relatively common, accounting for approximately 24% of all new cancers in the United States. CAR T cells have great potential for urinary system tumors. This review summarizes the latest developments of CAR T cell therapy in urinary system tumors, including kidney cancer, bladder cancer, and prostate cancer, and also outlines the various CAR T cell generations and their pathways and targets that have been developed thus far. Finally, the current advantages, problems, and side effects of CAR T cell therapy are discussed in depth, and potential future developments are proposed in view of current shortcomings.
MEMBER ACCOUNT
登录成功会直接打开下一页。
